London, 29-30 April
Latest News
Upcoming Events
Amphista will be attending and/or presenting at the following conferences. If you would like to meet with us, please email info@amphista.com
Protein Degradation in Focus Symposium
Dundee, 19-22 May
Amphista Therapeutics Appoints CBO, Beverley Carr
Cambridge, England, 1 November 2021 – Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the appointment of a Chief Business Officer (CBO), Beverley Carr. Amphista’s CEO Dr Nicola Thompson said, “On behalf of the Amphista team, I am thrilled to welcome Beverley as our CBO. Beverley brings a wealth […]
Amphista Therapeutics Appoints New Chairman, Joshua T. Brumm
Glasgow, UK, 21 September 2021 – Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the appointment of Joshua T. Brumm as its new Independent Chairman, succeeding Satish Jindal. Amphista’s CEO Dr Nicola Thompson said, “On behalf of the Amphista team I am thrilled to welcome someone of Josh’s calibre […]
Amphista Therapeutics Expands Research Team by Appointing Martin O’Rourke as Head of Drug Discovery and James Osborne as Director of Chemistry
Amphista Therapeutics Expands Research Team by Appointing Martin O’Rourke as Head of Drug Discovery and James Osborne as Director of Chemistry Glasgow, Scotland, 28 June 2021 – Amphista Therapeutics, a Targeted Protein Degradation (TPD) biopharmaceutical company creating first-in-class cancer therapeutics that harness the body’s natural processes to remove disease-causing proteins selectively and efficiently, today […]